研究表明,20 mg/kg剂量的VRC07-523LS皮下给药适合24周的给药间隔,而较短的间隔(<8周)适合低剂量PGT121。总的来说,VRC07-523LS和PGT121单独或联合给药是安全且耐受性良好的,可进一步研究作为HIV感染的长效预防技术。 参考文献: 1...
VRC07-523LS 结构式图片 扩展信息 VIP试用医疗器械查询APP下载客服中心常见问题数据可视化数据分析挖掘系统网站地图业务介绍友情链接 400-678-0778 投诉热线: (023) 6262 8397 邮箱: tousu@yaozh.com QQ: 236960938 友情链接: 药物在线 药品注册查询 临床试验查询 参比制剂目录 康洲大数据 Copyrigh...
We performed a cross-protocol analysis of three clinical trials and included data from a total of 146 adults without HIV who received intravenous (n=95) or subcutaneous (n=51) VRC07-523LS, either alone ('single';n=100) or in combination with 1 or 2 other mAbs ('combined';n=46). ...
METHODS. VRC07–523LS, 80 mg/dose, was administered subcutaneously after birth to non-breastfed (cohort 1; N = 11, enrolled in USA) and breastfed (cohort 2; N = 11, enrolled in South Africa and Zimbabwe) infants exposed to HIV-1. Breastfed infants (cohort 2) received a second 100...
METHODS. In this phase 1, open-label trial, we evaluated the safety and pharmacokinetics of 5 mg/kg 10E8VLS administered alone, or concurrently with 5 mg/kg VRC07-523LS, via s.c. injection to healthy non鈥揌IV-infected individuals. RESULTS. Eight participants received either 10E8VLS alone...
The purpose of this trial is to provide safety, pharmacokinetic (PK) and functional activity data of VRC07-523LS and PGT121 when administered subcutaneously (SC) to young South African women. Going forward, the aim is to select the ideal dose and/or monoclonal antibody for co-formulation and...
PHASE 1 TRIAL OF CAP256V2LS AND VRC07-523LS ANTIBODIES AMONG WOMEN IN SOUTH AFRICAMahomed, SharanaGarrett, NigelCapparelli, EdmundOsman, FarzanaMkhize, Nonhlanhla N.Archary, DersereeSerebryannyy, LeonidCastro, MikeMcDermott, Adrian B.